key: cord-0910725-frbfhy2j authors: Lieu, Anthony; Mah, Jordan; Church, Deirdre title: A Case of Multisystem Inflammatory Syndrome in Adults Following Natural Infection and Subsequent Immunization date: 2021-12-24 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.12.339 sha: fc98734c0b54dc15feda937eae0c5c9a6cddde57 doc_id: 910725 cord_uid: frbfhy2j Multisystem Inflammatory Syndrome in Adults is a rare and life-threatening complication that follows natural COVID-19 infection, primarily affecting young unvaccinated adults. This complication is seldomly described following vaccination, which would have important implications for this population's vaccination timing and platform. COVID-19 vaccines are extremely effective; however, the risk of rare adverse events needs to be balanced with the vaccination benefits. Multisystem Inflammatory Syndrome in Adults is a rare and life-threatening complication that follows natural COVID-19 infection, primarily affecting young unvaccinated adults. This complication is seldomly described following vaccination, which would have important implications for this population's vaccination timing and platform. COVID-19 vaccines are extremely effective; however, the risk of rare adverse events needs to be balanced with the vaccination benefits. A 21-year-old female presented to the emergency department (ED) with a 2-day history of chest pain, dyspnea, and leg edema. She previously tested positive for SARS-CoV-2 Alpha variant infection six-weeks prior to this acute illness, with nasopharyngeal (NP) polymerase chain reaction testing. She was asymptomatic at that time, with the test performed in the context of workplace exposure. 27-days after she tested positive, she received her first dose of mRNA vaccine (Moderna) without immediate adverse reactions. 10-days after her vaccination, she developed an acute-onset frontal headache associated with nausea, vomiting, and diarrhea. Over the next 7-days, a rash appeared with fever, and she sought medical attention from her General Practitioner, who diagnosed her with an allergic reaction. Her symptoms were later associated with progressive shortness of breath and chest pain, leading to her ED presentation ( Figure 1 ). She was a previously healthy, life-long non-smoker, and her ethnicity was Haitian. On examination, her temperature was 38.0 o C, with a blood pressure of 80/50 mmHg, heart rate of 120 beats/min, respiratory rate of 28 breaths/minute, and normal oxygen saturation on ambient air. Physical exam revealed a convalescent pink maculopapular rash involving the trunk and extremities, mild erythema of the tongue, and moderate bilateral leg edema. Her initial laboratory revealed leukocytosis, elevated inflammatory markers, and cardiac troponins. COVID-19 IgG serology directed towards nucleocapsid protein was positive. A chest x-ray was unremarkable, and a transthoracic echocardiogram (TTE) showed early signs of pericarditis, including a reduced left ventricular ejection function (LVEF) with global hypokinesis and trace pericardial effusion. Respiratory pathogen panel and SARS-CoV-2 PCR performed from the NP swab were negative, including enterovirus and adenovirus. Given her clinical picture of shock, she received fluid resuscitation, broad-spectrum antibiotics and was admitted to the Intensive Care Unit (ICU) to initiate inotropes. She fulfilled the Centers for Disease Control and Prevention (CDC) case definition for Multisystem Inflammatory Syndrome in Adults (MIS-A). She was started on a 5-day course of intravenous glucocorticoids with a taper, intravenous immunoglobulins, and aspirin ( Figure 1 ). Cardiogenic shock ensued over the next 48 hours despite inotropic support, and she required intubation due to hypoxic respiratory failure. She had a precipitous decline in cardiac function as documented on serial TTEs, with her nadir LVEF falling to 5%. Upon multidisciplinary discussion with various subspecialties, Anakinra, an interleukin-1 inhibitor, was initiated for cytokine storm and MIS-A. Despite these therapies, she had persistent hypoxic failure and vasoplegia requiring venousarterial extracorporeal membrane oxygenation (VA-ECMO). Her clinical status improved over the next few days, and repeated echocardiograms demonstrated LVEF recovery and improvement of inflammatory markers (Tables 1 & 2) . She was weaned off vasopressors, inotropes, VA-ECMO, and extubated. Her ICU stay was complicated by a cerebellar stroke, right common femoral artery thrombus, and critical illness polyneuropathy. MIS-A is a rare and potentially life-threatening complication of natural infection of COVID-19, commonly requiring acute care and often intensive care with hemodynamic support. Despite many case reports and case series, the true incidence is not known (Morris et al., 2020) . However, there have only been a handful of cases reports describing this severe complication following SARS-CoV-2 immunization, all of which had prior exposure to COVID-19 or proven laboratory serology to SARS-CoV-2 nucleocapsid IgG antibody (Salzman et al., 2021; Uwaydah et al., 2021) . Common features of these patients included their young age (18-44 years old), prior mild or asymptomatic COVID-19 infection, and the type of vaccine received (mRNA) (Salzman et al., 2021) . Younger age and mRNA vaccine platforms are associated with immunogenicity and potentially at higher risk of inducing MIS-A after natural infection (Salzman et al., 2021) . However, given the scarcity of the MIS-A cases following vaccination, little is understood about this entity, and suspected cases should be reported to the CDC. It is well described that after natural infection with COVID-19, vaccination elicits a more robust immune response than those not previously exposed and is often associated with systemic symptoms, including fever (Krammer et al., 2021) . We associate this potent immune response as generating better immunity; however, this can also theoretically lead to hyperinflammation and a dysregulated immune system which can paradoxically cause harm to the host. Of the two mRNA vaccines, Moderna has been more immunogenic, which our patient had received (Steensels et al., 2021) . The vaccine may have triggered an already primed immune system, causing a cytokine storm leading to a rapidly progressive, severe cardiac illness in an otherwise healthy young adult. This may raise questions about the optimal timing of vaccination following natural infection for young adults. It is important to note that all cases of MIS-A that occurred after vaccination were described after natural infection with COVID-19, and it is impossible to determine the causality based on these reports. The CDC and many healthcare jurisdictions suggest vaccination after SARS-CoV-2 following the patient's clinical recovery and isolation lifted (CDC, 2021; Alberta Health Services, 2021) . However, for patients diagnosed with MIS-A/C, the CDC recommends delaying vaccination by 90-days after diagnosis and clinical recovery but excludes patients who developed MIS-A/C following vaccination (CDC, 2021) . There is general agreement that individuals who have been previously infected with COVID-19 should be vaccinated. However, there is little guidance on which vaccine is appropriate and how many doses are required. Several studies have shown that most recovered COVID-19 patients develop antibodies against SARS-CoV-2, lasting at least 4-8 months (Dan et al., 2021) . This raises questions about the optimal timing of vaccination following COVID-19 infection, particularly in young and healthy adults. Until further studies, we propose considering the delay of immunization for 90-days following natural infection given the rare but potentially severe risk of exacerbating MIS-A if the vaccine is given too prematurely. There is evidence suggesting there are long-lasting neutralizing antibody responses which may last up to 8-12 months in individuals who had previously had severe COVID-19 infection (Lau et al., 2021; Sherina et al., 2021) . Our case may represent an exceptionally rare circumstance, where vaccination could be potentially deferred to a later period 90-days after prior infection. As COVID-19 vaccines have been demonstrated to be extremely effective in preventing infection, the risk of rare adverse events following immunization needs to be balanced with the benefits of vaccination. We report a case of MIS-A which followed natural COVID-19 infection and subsequent SARS-CoV-2 mRNA immunization, associated with high morbidity. Clinician reporting of MIS-A following vaccination is crucial in monitoring this potentially rare and unrecognized adverse event. Only a handful of case reports have so far described severe progressive MIS-A following vaccination, all of which have followed natural infection and the optimal timing of COVID-19 immunization in this young population remains to be elucidated. Anthony Lieu and Jordan Mah contributed equally to the conception and writing of the manuscript. Deirdre Church contributed to the editing and revision of the manuscript. COVID-19 Vaccine Frequently Asked Questions 2021 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine Neutralizing antibody titres in SARS-CoV-2 infections Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination We would like to thank all the subspecialist services who were involved in this patient's care. We obtained direct consent from the patient for publication of this as a case report. There was no ethics approval sought for writing of this manuscript. The authors received no financial support for the writing of this case report.